Sign In
Buy SMID
$29.95
-1.26 (-4.04%)
At Close: Jun 03, 2026
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
08:00am, Thursday, 30'th Jan 2025
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
08:00am, Thursday, 30'th Jan 2025
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
07:00am, Thursday, 30'th Jan 2025
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
07:00am, Thursday, 30'th Jan 2025
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
07:00am, Thursday, 30'th Jan 2025
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision canc
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
07:00am, Thursday, 30'th Jan 2025
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
04:05pm, Wednesday, 29'th Jan 2025
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
04:05pm, Wednesday, 29'th Jan 2025
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
08:00am, Wednesday, 29'th Jan 2025
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference
08:00am, Wednesday, 29'th Jan 2025
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
07:30am, Wednesday, 29'th Jan 2025
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
07:30am, Wednesday, 29'th Jan 2025
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody thera
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
07:00am, Wednesday, 29'th Jan 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
07:00am, Wednesday, 29'th Jan 2025
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
08:00am, Tuesday, 28'th Jan 2025
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
